Molecular Architecture of SF3b and Structural Consequences of Its Cancer-Related Mutations

Constantin Cretu1, Jana Schmitzová1, Almudena Ponce-Salvatierra2

  • 1Research Group Macromolecular Crystallography, Max Planck Institute for Biophysical Chemistry, Am Fassberg 11, 37077 Göttingen, Germany.

Molecular Cell
|October 11, 2016
PubMed

Insights

The SF3b complex

Area of Science:

  • Molecular Biology
  • Structural Biology
  • Biochemistry

Background:

  • The SF3b complex, a key component of the U2 small nuclear ribonucleoprotein (snRNP), is crucial for pre-mRNA splicing.
  • Mutations in SF3B1/SF3b155, the largest SF3b subunit, are associated with cancer and aberrant branch site selection.

Purpose of the Study:

  • To elucidate the crystal structure of the human SF3b core complex.
  • To understand how SF3b155's HEAT domain conformation is stabilized.
  • To map the binding sites of branch site-associated proteins within the SF3b complex.

Main Methods:

  • X-ray crystallography to determine the structure of the human SF3b core complex.
  • Protein-protein crosslinking to identify interacting partners and their locations.
  • Structural analysis to investigate the role of SF3b155 mutations.

Main Results:

  • The crystal structure reveals how SF3b155's HEAT domain is stabilized by interactions with SF3b130, SF3b10, and SF3b14b.
  • p14 and U2AF65 were localized to SF3b155's HEAT-repeat superhelix, forming a composite RNA-binding platform with SF3b14b.
  • Cancer-associated mutations in SF3b155 affect the tertiary structure and surface properties of the HEAT superhelix near p14 and U2AF65 binding sites.

Conclusions:

  • The molecular architecture of SF3b provides insights into the spatial arrangement of cancer-related SF3b155 mutations.
  • This structural understanding advances knowledge of SF3b function and the impact of mutations on splicing.
  • The study reveals a composite RNA-binding platform critical for spliceosome assembly and function.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
6.9K
Mismatch Repair01:36

Mismatch Repair

Overview
44.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
15.3K